Oric Pharmaceuticals

Oric is an operating company—a clinical-stage biopharmaceutical firm, not a family office or investment entity. It develops its own drug candidates in-house and is traded publicly on Nasdaq under the ticker ORIC. The firm's capital is deployed directly into its own research programs, not into third-party funds or external portfolio companies.

The firm focuses exclusively on the biology of cancer drug resistance. Its pipeline targets specific mechanisms tumors use to evade therapies, including EGFR/HER2 mutations in lung cancer and PRC2 pathways in prostate cancer. The thesis is that by blocking these resistance pathways, Oric's drugs can restore or extend the efficacy of existing treatments.

Oric does not have an investment committee in the traditional allocator sense—capital allocation decisions are corporate R&D budget decisions made by CEO Jacob Chacko and the executive team, under board oversight chaired by Richard Heyman. Funding is raised through public equity markets rather than LP commitments, and the board approves major expenditures including clinical trial initiations.

Oric uses a hybrid model. Internal medicinal chemistry and biology teams at its South San Francisco and San Diego sites generate proprietary small-molecule inhibitors. The firm also in-licenses promising compounds, as it did with ORIC-114, a brain-penetrant EGFR inhibitor licensed from a South Korean biotech. This mix of internal discovery and external licensing allows it to target resistance mechanisms regardless of chemical origin.

There is no publicly disclosed Oric-specific foundation or philanthropic vehicle. Like most development-stage biotechs, any charitable activity is typically conducted at the corporate level or through patient advocacy partnerships, rather than through a separate philanthropic entity.

Oric does not operate as a co-investor in the typical GP sense. Its collaborations—such as the licensing agreements with Taiho Pharmaceutical—are structured as traditional biopharma licensing deals with upfront payments, milestone payments, and royalties, rather than equity co-investments in portfolio companies.

Oric is publicly traded and funded through equity capital markets. The firm raised $120 million in its April 2020 IPO and has since completed follow-on offerings. Its shareholder base includes institutional biotech investors, not a single-family wealth source. The firm's most recent balance sheet disclosures indicate cash and equivalents sufficient to fund operations into 2026 or early 2027.